Artemis Therapeutics, Inc. (OTCMKTS:INKSD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Artemis Therapeutics, Inc. (OTCMKTS:INKSD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Story continues below

Item 5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

On December 16, 2016, New York Global Innovations Inc., or the
Company, filed a Certificate of Amendment with the Secretary of
State of the State of Delaware, or the Certificate of Amendment,
to which the Company: (i) effected a one-for-fifty (1:50) reverse
stock split of the Companys issued and outstanding shares of
common stock, or the Stock Split, (ii) decreased the number of
authorized shares of common stock from 75,000,000 to 51,000,000
and decreased the number of authorized shares of preferred stock
from 10,000,000 to 200,000, or the Authorized Capital Change, and
(iii) changed the name of the Company to Artemis Therapeutics,
Inc., or the Name Change. The Stock Split, Authorized Capital
Change and Name Change will take effect on December 20, 2016. A
copy of the Certificate of Amendment is attached hereto as
Exhibit 3.1 and is incorporated herein by reference.
Upon the effectiveness of the Stock Split, the Companys issued
and outstanding shares of common stock decreased from
approximately 69.5 million shares to approximately 1.3 million
shares of common stock, all with a par value of $0.01.
Fractional shares resulting from the Stock Split were rounded
up to the next whole number. In addition, upon the
effectiveness of the Stock Split, the Companys Series B
Preferred Stock will automatically be converted into
approximately 3.8 million shares of common stock (after the
Stock Split is effectuated).
The Board of Directors approved the Stock Split, Authorized
Capital Change and Name Change on November 2, 2016 and the
holders of a majority of the Companys outstanding common stock
approved the Stock Split and Authorized Capital Change on
November 9, 2016. to Section 242 of the Delaware General
Corporation law, the Name Change did not require stockholder
approval.
The foregoing description of the Certificate of Amendment does
not purport to be complete and is qualified in its entirety by
reference to the full text of the Certificate of Amendment, a
copy of which is filed as Exhibit 3.1 hereto and incorporated by
reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
3.1
Certificate of Amendment dated December 16, 2016.


About Artemis Therapeutics, Inc. (OTCMKTS:INKSD)

New York Global Innovations Inc. is a shell company. The Company developed, marketed and sold customized authentication solutions designed to enhance the security of documents and branded products for protection from counterfeiting. The Company is seeking an acquisition or merger candidate. The Company has not generated any revenue.

Artemis Therapeutics, Inc. (OTCMKTS:INKSD) Recent Trading Information

Artemis Therapeutics, Inc. (OTCMKTS:INKSD) closed its last trading session 00.00 at 1.00 with shares trading hands.

An ad to help with our costs